Published in Nat Biotechnol on January 17, 2010
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol (2013) 2.22
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov (2014) 2.20
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 1.56
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol (2014) 1.48
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem (2012) 1.46
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature (2014) 1.35
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J (2012) 1.27
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun (2012) 1.19
Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin (2010) 1.15
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity (2013) 1.07
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol (2012) 1.07
The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol (2012) 1.06
Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05
Biosimilar, biobetter and next generation therapeutic antibodies. MAbs (2011) 1.05
Maternal antibody persistence: a neglected life-history trait with implications from albatross conservation to comparative immunology. Proc Biol Sci (2011) 1.02
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs (2011) 1.02
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn (2012) 1.01
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One (2013) 0.99
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 0.98
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs (2013) 0.98
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med (2014) 0.95
Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol (2010) 0.94
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs (2015) 0.94
Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs (2013) 0.93
Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs (2014) 0.93
Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods (2013) 0.92
Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res (2013) 0.92
Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res (2013) 0.91
Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs (2011) 0.90
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88
Clinical chemistry of human FcRn transgenic mice. Mamm Genome (2011) 0.88
Strategies for preventing mucosal cell-associated HIV transmission. J Infect Dis (2014) 0.88
Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem (2013) 0.88
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem (2014) 0.87
Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta (2014) 0.87
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front Immunol (2015) 0.86
A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics (2015) 0.86
Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One (2012) 0.85
A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin. Toxicon (2014) 0.85
Regulation of immune responses by the neonatal fc receptor and its therapeutic implications. Front Immunol (2015) 0.85
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem (2014) 0.85
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol (2015) 0.84
Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem (2013) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis (2016) 0.83
Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol (2011) 0.83
Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol Cell Proteomics (2014) 0.83
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs (2014) 0.83
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS (2015) 0.82
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs (2016) 0.82
A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. MAbs (2014) 0.81
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets (2014) 0.81
Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs (2014) 0.81
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). J Biol Chem (2014) 0.80
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. J Virol (2016) 0.80
Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. MAbs (2015) 0.80
Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev (2017) 0.80
Engineering humoral immunity as prophylaxis or therapy. Curr Opin Immunol (2015) 0.79
Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. MAbs (2013) 0.79
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs (2015) 0.79
Chimeric antibodies with extended half-life in ferrets. Influenza Other Respir Viruses (2014) 0.78
Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc Natl Acad Sci U S A (2015) 0.78
An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proc Natl Acad Sci U S A (2014) 0.78
Selection of nanobodies that target human neonatal Fc receptor. Sci Rep (2013) 0.78
Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs (2016) 0.78
Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors. Biomed Res Int (2014) 0.78
Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. MAbs (2016) 0.77
Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. Immunol Lett (2014) 0.77
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs (2015) 0.77
Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs (2016) 0.77
Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs (2014) 0.77
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev (2017) 0.77
Next generation of antibody therapy for cancer. Chin J Cancer (2011) 0.76
Antibody-based concepts for multipurpose prevention technologies. Antiviral Res (2013) 0.76
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol (2015) 0.76
Differential regulation of angiogenesis using degradable VEGF-binding microspheres. Biomaterials (2016) 0.76
Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications. Sci Rep (2015) 0.76
A targeted RNAi screen identifies factors affecting diverse stages of receptor-mediated transcytosis. J Cell Biol (2017) 0.75
Targeted FcγR mediated clearance by a biparatopic bispecific antibody. J Biol Chem (2017) 0.75
Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther (2015) 0.75
Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol (2016) 0.75
Enhancement of antibody functions through Fc multiplications. MAbs (2017) 0.75
FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric-coated capsules in cynomolgus macaques. Pharmacol Res Perspect (2016) 0.75
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs (2017) 0.75
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem (2003) 2.03
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther (1999) 1.88
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol (2008) 1.74
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem (1994) 1.69
Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem (2006) 1.42
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol (2005) 1.42
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res (2006) 1.39
Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother (1993) 1.10
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol (2003) 3.09
Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 2.79
The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med (2003) 2.63
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest (2006) 2.16
Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A (2011) 2.14
Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A (2008) 2.12
Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol (2007) 1.86
Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A (2008) 1.82
In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med (2006) 1.79
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther (2008) 1.61
The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest (2004) 1.59
Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res (2008) 1.50
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 1.47
Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Immunity (2002) 1.47
CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc Natl Acad Sci U S A (2011) 1.41
Thoroughly sampling sequence space: large-scale protein design of structural ensembles. Protein Sci (2002) 1.39
Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol (2003) 1.38
Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest (2005) 1.36
Accelerated wound healing of alkali-burned corneas in MRL mice is associated with a reduced inflammatory signature. Invest Ophthalmol Vis Sci (2005) 1.31
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs (2011) 1.27
Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J Mol Biol (2004) 1.25
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood (2009) 1.25
Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion. J Biol Chem (2005) 1.24
Rational design and engineering of therapeutic proteins. Drug Discov Today (2003) 1.24
Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood (2002) 1.23
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today (2007) 1.22
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol (2008) 1.22
A simple method for modeling transmembrane helix oligomers. J Mol Biol (2003) 1.19
Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol (2011) 1.16
T cell knockout mice have diminished alveolar bone loss after oral infection with Porphyromonas gingivalis. FEMS Immunol Med Microbiol (2002) 1.16
Mutations in sterol O-acyltransferase 1 (Soat1) result in hair interior defects in AKR/J mice. J Invest Dermatol (2010) 1.15
NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. J Immunol (2007) 1.14
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood (2008) 1.14
Genetic influence on immune phenotype revealed strain-specific variations in peripheral blood lineages. Physiol Genomics (2008) 1.10
Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol (2010) 1.09
Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB. J Exp Med (2006) 1.08
Increased detection of structural templates using alignments of designed sequences. Proteins (2003) 1.07
Membrane channel structure of Helicobacter pylori vacuolating toxin: role of multiple GXXXG motifs in cylindrical channels. Proc Natl Acad Sci U S A (2004) 1.06
A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol (2011) 1.06
A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol (2006) 1.06
A C alpha-H...O hydrogen bond in a membrane protein is not stabilizing. J Am Chem Soc (2004) 1.04
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood (2012) 1.03
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs (2011) 1.02
Designing proteins for therapeutic applications. Curr Opin Struct Biol (2003) 1.01
The neonatal FcR-mediated presentation of immune-complexed antigen is associated with endosomal and phagosomal pH and antigen stability in macrophages and dendritic cells. J Immunol (2011) 0.99
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol (2012) 0.99
A mouse model of generalized non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol (2010) 0.99
NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas. Cancer Res (2008) 0.98
ExQuest, a novel method for displaying quantitative gene expression from ESTs. Genomics (2004) 0.97
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res (2007) 0.97
Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A (2011) 0.97
A de novo redesign of the WW domain. Protein Sci (2003) 0.96
Modulation of antibody effector function. Exp Cell Res (2011) 0.95
IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood (2013) 0.94
Cdcs1 a major colitis susceptibility locus in mice; subcongenic analysis reveals genetic complexity. Inflamm Bowel Dis (2010) 0.93
Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol (2010) 0.92
Coronary artery disease from isolated non-H2-determined incompatibilities in transplanted mouse hearts. Transplantation (2011) 0.91
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci (2010) 0.90
Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol (2012) 0.90
A model of the closed form of the nicotinic acetylcholine receptor m2 channel pore. Biophys J (2004) 0.89
Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D. J Immunol (2002) 0.89
Clinical chemistry of human FcRn transgenic mice. Mamm Genome (2011) 0.88